Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (21157)	9/5/2006 5:35:54 PM
From: OldAIMGuy	Read Replies (1) \| Respond to of 52153

Hi B, Re: Discernable Pattern............ Looking at the NASDAQ Biotech Index ETF it appears this last "low" was a higher low than the previous two over about a three year period. We're back to the 26 week moving average and some accumulation building for better than a year. I don't own much in the way of individual biotechs any more. Just the index funds. Best regards, Tom

To: Biomaven who wrote (21157)	9/5/2006 8:21:55 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 52153

More than just a few biotechs have been creeping up. My take is that it is sector rotation. Maybe even more than that, it might be speculative money dancing away from housing and looking for the next wave with a good upside potential. Biotech fits the bill - so might gold and silver stocks? steve

To: Biomaven who wrote (21157)	9/6/2006 3:51:00 AM
From: Doc Bones	Read Replies (3) \| Respond to of 52153

The biggest trend I see is a bounce in risk-tolerance and appetite for tech-spec stocks. In May there was a big drop in tech stocks, and it had started earlier in biotech. There was talk about Central Banks, e.g. in Japan, soaking up liquidity. which seemed to hit speculative stocks hard, and rumors of Hedge Funds collapsing. Then in August they bounced back, why I don't know, but I'll take it. finance.yahoo.com I don't see much pattern other than the riskier stocks making the biggest moves, e.g. CIPH followed the trend closely. Doc p.s. Thanks for your list of top holdings, Peter, I'm always interested.

To: Biomaven who wrote (21157)	9/19/2006 7:33:55 PM
From: dr.praveen	Read Replies (2) \| Respond to of 52153

Ibuprofen May Reduce Protective Effects of Aspirin Sue Hughes <I have 3 bio's in common with you now :-) pozn,regn n mnta> September 12, 2006 — The US Food and Drug Administration (FDA) has notified healthcare professionals and consumers that taking ibuprofen for pain relief may interfere with the benefits of aspirin taken for heart disease. Ibuprofen can interfere with the antiplatelet effect of low-dose aspirin (81 mg/day), which may render aspirin less effective when used for cardioprotection and stroke prevention, according to an alert from MedWatch, the FDA's safety information and adverse event reporting program. The FDA recommends that consumers contact their healthcare professional for more information on the timing of when to take these 2 medicines, so that both medicines can be effective. In a note to healthcare professionals, the FDA gives the following advice: With occasional use of ibuprofen, there is likely to be minimal risk from any attenuation of the antiplatelet effect of low-dose aspirin, because of the long-lasting effect of aspirin on platelets. Patients who use immediate-release aspirin (not enteric-coated) and take a single dose of ibuprofen, 400 mg, should dose the ibuprofen at least 30 minutes or longer after aspirin ingestion, or more than 8 hours before aspirin ingestion to avoid attenuation of aspirin’s effect. Recommendations about the timing of concomitant use of ibuprofen and enteric-coated low-dose aspirin cannot be made based upon available data, which has shown that the antiplatelet effect of enteric-coated low-dose aspirin is attenuated when 400 mg of ibuprofen is dosed 2, 7, and 12 hours after aspirin. Other nonselective over-the-counter nonsteroidal anti-inflammatory drugs should be viewed as having the potential to interfere with the antiplatelet effect of low-dose aspirin unless proven otherwise. Analgesics that do not interfere with the antiplatelet effect of low-dose aspirin (such as acetaminophen or narcotics) should be considered for high-risk populations.